Comprehensive landscape and future perspectives of non-coding RNAs in esophageal squamous cell carcinoma, a bibliometric analysis from 2008 to 2023
Conclusion: Overall, research on ncRNAs in ESCC remains strong. Previous research has mainly focused on the basic research, with a focus on the mechanism of ncRNAs in the occurrence, development, diagnosis, treatment, and prognosis of ESCC. Combining current research with emerging disciplines to further explore its mechanisms of action or shifting the focus of research from preclinical research to clinical research based on diagnosis, treatment, and prognosis, will be the main breakthrough in this field in the future.PMID:38450329 | PMC:PMC10915033 | DOI:10.3389/pore.2024.1611595 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 7, 2024 Category: Pathology Authors: Jiaxin Wu Yuanying Wang Yi Cheng Li Cheng Lushun Zhang Source Type: research

Comprehensive landscape and future perspectives of non-coding RNAs in esophageal squamous cell carcinoma, a bibliometric analysis from 2008 to 2023
Conclusion: Overall, research on ncRNAs in ESCC remains strong. Previous research has mainly focused on the basic research, with a focus on the mechanism of ncRNAs in the occurrence, development, diagnosis, treatment, and prognosis of ESCC. Combining current research with emerging disciplines to further explore its mechanisms of action or shifting the focus of research from preclinical research to clinical research based on diagnosis, treatment, and prognosis, will be the main breakthrough in this field in the future.PMID:38450329 | PMC:PMC10915033 | DOI:10.3389/pore.2024.1611595 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 7, 2024 Category: Pathology Authors: Jiaxin Wu Yuanying Wang Yi Cheng Li Cheng Lushun Zhang Source Type: research

Comprehensive landscape and future perspectives of non-coding RNAs in esophageal squamous cell carcinoma, a bibliometric analysis from 2008 to 2023
Conclusion: Overall, research on ncRNAs in ESCC remains strong. Previous research has mainly focused on the basic research, with a focus on the mechanism of ncRNAs in the occurrence, development, diagnosis, treatment, and prognosis of ESCC. Combining current research with emerging disciplines to further explore its mechanisms of action or shifting the focus of research from preclinical research to clinical research based on diagnosis, treatment, and prognosis, will be the main breakthrough in this field in the future.PMID:38450329 | PMC:PMC10915033 | DOI:10.3389/pore.2024.1611595 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 7, 2024 Category: Pathology Authors: Jiaxin Wu Yuanying Wang Yi Cheng Li Cheng Lushun Zhang Source Type: research

Comprehensive landscape and future perspectives of non-coding RNAs in esophageal squamous cell carcinoma, a bibliometric analysis from 2008 to 2023
Conclusion: Overall, research on ncRNAs in ESCC remains strong. Previous research has mainly focused on the basic research, with a focus on the mechanism of ncRNAs in the occurrence, development, diagnosis, treatment, and prognosis of ESCC. Combining current research with emerging disciplines to further explore its mechanisms of action or shifting the focus of research from preclinical research to clinical research based on diagnosis, treatment, and prognosis, will be the main breakthrough in this field in the future.PMID:38450329 | PMC:PMC10915033 | DOI:10.3389/pore.2024.1611595 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 7, 2024 Category: Pathology Authors: Jiaxin Wu Yuanying Wang Yi Cheng Li Cheng Lushun Zhang Source Type: research

Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Conclusion: This study is the first to provide insights into the characteristics, treatment patterns, and outcomes of CML patients treated with TKIs in Hungarian clinical practice between 2011 and 2019. We found slightly lower OS rates compared to other European countries, however, there was a statistically significant improvement in 4-year OS during the study period. The management of CML was in line with international guidelines and recommendations.PMID:38444749 | PMC:PMC10913892 | DOI:10.3389/pore.2024.1611497 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 6, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research

Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Conclusion: This study is the first to provide insights into the characteristics, treatment patterns, and outcomes of CML patients treated with TKIs in Hungarian clinical practice between 2011 and 2019. We found slightly lower OS rates compared to other European countries, however, there was a statistically significant improvement in 4-year OS during the study period. The management of CML was in line with international guidelines and recommendations.PMID:38444749 | PMC:PMC10913892 | DOI:10.3389/pore.2024.1611497 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 6, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research

Editorial: Pathology and Oncology Research: addressing publication ethics issues
Pathol Oncol Res. 2024 Feb 14;30:1611691. doi: 10.3389/pore.2024.1611691. eCollection 2024.NO ABSTRACTPMID:38420138 | PMC:PMC10900982 | DOI:10.3389/pore.2024.1611691 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 29, 2024 Category: Pathology Authors: J ózsef Tímár Andrea Lad ányi Anna Sebesty én L ászló Kopper Source Type: research

Editorial: Pathology and Oncology Research: addressing publication ethics issues
Pathol Oncol Res. 2024 Feb 14;30:1611691. doi: 10.3389/pore.2024.1611691. eCollection 2024.NO ABSTRACTPMID:38420138 | PMC:PMC10900982 | DOI:10.3389/pore.2024.1611691 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 29, 2024 Category: Pathology Authors: J ózsef Tímár Andrea Lad ányi Anna Sebesty én L ászló Kopper Source Type: research

Editorial: Pathology and Oncology Research: addressing publication ethics issues
Pathol Oncol Res. 2024 Feb 14;30:1611691. doi: 10.3389/pore.2024.1611691. eCollection 2024.NO ABSTRACTPMID:38420138 | PMC:PMC10900982 | DOI:10.3389/pore.2024.1611691 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 29, 2024 Category: Pathology Authors: J ózsef Tímár Andrea Lad ányi Anna Sebesty én L ászló Kopper Source Type: research

Editorial: Pathology and Oncology Research: addressing publication ethics issues
Pathol Oncol Res. 2024 Feb 14;30:1611691. doi: 10.3389/pore.2024.1611691. eCollection 2024.NO ABSTRACTPMID:38420138 | PMC:PMC10900982 | DOI:10.3389/pore.2024.1611691 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 29, 2024 Category: Pathology Authors: J ózsef Tímár Andrea Lad ányi Anna Sebesty én L ászló Kopper Source Type: research

Editorial: Pathology and Oncology Research: addressing publication ethics issues
Pathol Oncol Res. 2024 Feb 14;30:1611691. doi: 10.3389/pore.2024.1611691. eCollection 2024.NO ABSTRACTPMID:38420138 | PMC:PMC10900982 | DOI:10.3389/pore.2024.1611691 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 29, 2024 Category: Pathology Authors: J ózsef Tímár Andrea Lad ányi Anna Sebesty én L ászló Kopper Source Type: research

LINAC-based SBRT in treating early-stage NSCLC patients-single institution experience and survival data analysis
Conclusion: In the treatment of early-stage NSCLC, LINAC-based SBRT can be a feasible alternative to surgery. Although we reported worse OS data in our patient cohort compared to the literature, the higher older average age and the initial worse general condition (ECOG1-2) in our patient cohort appear to be the reason for this difference. With the comparable local control and survival data and the favorable side effect profile, SBRT might be preferable over surgery in selected cases.PMID:38414671 | PMC:PMC10896905 | DOI:10.3389/pore.2024.1611589 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 28, 2024 Category: Pathology Authors: Árpád Kovács Krisztina Tr ási M árton Barabás Krist óf Gál Emese Csiki D ávid Sipos Judit Papp Mih ály Simon Source Type: research

LINAC-based SBRT in treating early-stage NSCLC patients-single institution experience and survival data analysis
Conclusion: In the treatment of early-stage NSCLC, LINAC-based SBRT can be a feasible alternative to surgery. Although we reported worse OS data in our patient cohort compared to the literature, the higher older average age and the initial worse general condition (ECOG1-2) in our patient cohort appear to be the reason for this difference. With the comparable local control and survival data and the favorable side effect profile, SBRT might be preferable over surgery in selected cases.PMID:38414671 | PMC:PMC10896905 | DOI:10.3389/pore.2024.1611589 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 28, 2024 Category: Pathology Authors: Árpád Kovács Krisztina Tr ási M árton Barabás Krist óf Gál Emese Csiki D ávid Sipos Judit Papp Mih ály Simon Source Type: research

Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment
Pathol Oncol Res. 2024 Feb 6;30:1611549. doi: 10.3389/pore.2024.1611549. eCollection 2024.ABSTRACTGlioblastoma is the most aggressive brain tumor with extremely poor prognosis in adults. Routine treatments include surgery, chemotherapy, and radiotherapy; however, these may lead to rapid relapse and development of therapy-resistant tumor. Glioblastoma cells are known to communicate with macrophages, microglia, endothelial cells, astrocytes, and immune cells in the tumor microenvironment (TME) to promote tumor preservation. It was recently demonstrated that Glioblastoma-derived extracellular vesicles (EVs) participate in bid...
Source: Pathology Oncology Research - February 21, 2024 Category: Pathology Authors: Jie Dai Yong Jiang Haoyue Hu Shuang Zhang Yue Chen Source Type: research

Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment
Pathol Oncol Res. 2024 Feb 6;30:1611549. doi: 10.3389/pore.2024.1611549. eCollection 2024.ABSTRACTGlioblastoma is the most aggressive brain tumor with extremely poor prognosis in adults. Routine treatments include surgery, chemotherapy, and radiotherapy; however, these may lead to rapid relapse and development of therapy-resistant tumor. Glioblastoma cells are known to communicate with macrophages, microglia, endothelial cells, astrocytes, and immune cells in the tumor microenvironment (TME) to promote tumor preservation. It was recently demonstrated that Glioblastoma-derived extracellular vesicles (EVs) participate in bid...
Source: Pathology Oncology Research - February 21, 2024 Category: Pathology Authors: Jie Dai Yong Jiang Haoyue Hu Shuang Zhang Yue Chen Source Type: research